Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer
NCT07664735Phase 1Recruiting
- Sponsor
- Outpace Bio
- Start
- Jun 2026
- Primary completion
- Jun 2030
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of OPB-201 in endometrial cancer (EC) and ovarian cancer, sponsored by Outpace Bio. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 2 years, Incidence of Dose-Limiting Toxicities at 28 days and 1 more. Started Jun 2026; status: recruiting.
02
Drugs
OPB-201
03
Conditions
endometrial cancer (EC)ovarian cancer
Beyond the preview
Go deeper on NCT07664735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07664735.